Stockscreener 앱 받기
65.69
8.85%
5.34
시간 외 거래:
65.39
-0.30
-0.46%
전일 마감가:
$60.35
열려 있는:
$63.1
하루 거래량:
862.84K
Relative Volume:
0.89
시가총액:
$1.34B
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-44.99
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+8.85%
1개월 성능:
+9.30%
6개월 성능:
+9,943%
1년 성능:
+6,039%
1일 변동 폭
$60.35
$66.59
1주일 범위
$53.29
$66.59
52주 변동 폭
$0.432
$66.92
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
65.69 | 1.23B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR Stock News - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 | NKTR Stock News - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Nigeria
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com UK
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st
Nektar Therapeutics stock price target raised to $121 from $99 at Jefferies - Investing.com Nigeria
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies - StreetInsider
Assessing Nektar Therapeutics (NKTR) Valuation Following Recent Share Price Surge - simplywall.st
Nektar Therapeutics Stock Analysis and ForecastInsider Buying Signals & Stay One Step Ahead of Risk Events - earlytimes.in
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? - Finviz
Nektar Therapeutics announces chief legal officer transition effective year-end By Investing.com - Investing.com India
Nektar Therapeutics Announces Chief Legal Officer Departure - TipRanks
Nektar Therapeutics announces chief legal officer transition effective year-end - Investing.com
Nektar Therapeutics Announces Chief Legal Officer Change - TradingView
Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma - HCPLive
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Will Nektar Therapeutics (ITH0) stock beat Nasdaq index returns2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Nektar at Jefferies: Biologics in Focus for New Indications By Investing.com - Investing.com Australia
Nektar at Jefferies: Biologics in Focus for New Indications - Investing.com
Nektar Therapeutics (NKTR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How big funds are accumulating Nektar Therapeutics (ITH0) stockMarket Rally & Long-Term Safe Investment Ideas - newser.com
Will Nektar Therapeutics (ITH0) stock profit from fiscal stimulusWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Is Nektar Therapeutics stock attractive for passive investorsJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com
How Nektar Therapeutics (ITH0) stock trades in high volatilityMarket Risk Analysis & Safe Entry Zone Tips - newser.com
What RSI levels show for Nektar Therapeutics (ITH0) stock2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Nektar TherapeuticsJuly 2025 Highlights & Verified Entry Point Signals - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Outlook & Daily Entry Point Alerts - newser.com
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics - Yahoo Finance
Using economic indicators to assess Nektar Therapeutics potential2025 Institutional Moves & Weekly Watchlist for Consistent Profits - newser.com
Can volume confirm reversal in Nektar Therapeutics2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
How geopolitical risks impact Nektar Therapeutics (ITH0) stock2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
What technical charts say about Nektar Therapeutics stockJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
2.16%
자본화:
|
볼륨(24시간):